Extensive androgen exposure and meningioma risk – A matched cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Extensive androgen exposure and meningioma risk – A matched cohort study. / Giraldi, Laura; Heerfordt, Ida M.; Windfeld-Mathiasen, Josefine; Dalhoff, Kim Peder; Andersen, Jon Trærup; Horwitz, Henrik.
In: Clinical Neurology and Neurosurgery, Vol. 239, 108217, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Extensive androgen exposure and meningioma risk – A matched cohort study
AU - Giraldi, Laura
AU - Heerfordt, Ida M.
AU - Windfeld-Mathiasen, Josefine
AU - Dalhoff, Kim Peder
AU - Andersen, Jon Trærup
AU - Horwitz, Henrik
N1 - Publisher Copyright: © 2024 The Authors
PY - 2024
Y1 - 2024
N2 - Introduction: Meningiomas frequently occur within the field of neuro-oncology, but it is unclear whether exogenous or imbalanced endogenous hormones are involved in the pathophysiology. A previous case-control study found an almost 20-fold increase in the risk of developing meningioma among users of androgenic anabolic steroids. We, therefore, investigated this hypothesis. Methods: We compared the incidence rate of meningioma in a cohort of males sanctioned for the use of androgenic anabolic steroids with age- and sex-matched controls with an identical enrollment date. Results: We followed 1189 males sanctioned for using androgenic anabolic steroids for a total of 13,305 person-years and found 0 cases of meningioma. The control cohort of 59,450 males was followed for a total of 654,938 person-years, and 16 were diagnosed with meningioma. Thus, the incidence rate ratio was 0 (95% CI: 0–12.8). Conclusion: We did not find any evidence supporting the hypothesis of an increased risk of meningioma development with the use of androgenic anabolic steroids. Due to the limited sample size, we cannot exclude androgenic anabolic steroids as a potential risk factor for meningioma development, despite the lack of apparent evidence in this study.
AB - Introduction: Meningiomas frequently occur within the field of neuro-oncology, but it is unclear whether exogenous or imbalanced endogenous hormones are involved in the pathophysiology. A previous case-control study found an almost 20-fold increase in the risk of developing meningioma among users of androgenic anabolic steroids. We, therefore, investigated this hypothesis. Methods: We compared the incidence rate of meningioma in a cohort of males sanctioned for the use of androgenic anabolic steroids with age- and sex-matched controls with an identical enrollment date. Results: We followed 1189 males sanctioned for using androgenic anabolic steroids for a total of 13,305 person-years and found 0 cases of meningioma. The control cohort of 59,450 males was followed for a total of 654,938 person-years, and 16 were diagnosed with meningioma. Thus, the incidence rate ratio was 0 (95% CI: 0–12.8). Conclusion: We did not find any evidence supporting the hypothesis of an increased risk of meningioma development with the use of androgenic anabolic steroids. Due to the limited sample size, we cannot exclude androgenic anabolic steroids as a potential risk factor for meningioma development, despite the lack of apparent evidence in this study.
KW - Androgenic anabolic steroids
KW - Cohort study
KW - Meningioma
KW - Pharmacology
KW - Testosterone
U2 - 10.1016/j.clineuro.2024.108217
DO - 10.1016/j.clineuro.2024.108217
M3 - Journal article
C2 - 38452714
AN - SCOPUS:85186704621
VL - 239
JO - Clinical Neurology and Neurosurgery
JF - Clinical Neurology and Neurosurgery
SN - 0303-8467
M1 - 108217
ER -
ID: 385692159